This HTML5 document contains 123 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
n18https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/
foafhttp://xmlns.com/foaf/0.1/
n24https://global.dbpedia.org/id/
dbpedia-ruhttp://ru.dbpedia.org/resource/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n20http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
n21https://druginfo.nlm.nih.gov/drugportal/name/
n16http://
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbpedia-nlhttp://nl.dbpedia.org/resource/
dbrhttp://dbpedia.org/resource/
dbpedia-jahttp://ja.dbpedia.org/resource/

Statements

Subject Item
dbr:Roche
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Antibody-drug_conjugate
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Genentech
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
dbo:product
dbr:Polatuzumab_vedotin
Subject Item
dbr:Monomethyl_auristatin_E
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Monoclonal_antibody_therapy
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Richter's_transformation
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:ATC_code_L01
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Diffuse_large_B-cell_lymphoma
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Polatuzumab_vedotin
rdf:type
dbo:MonoclonalAntibody n20:ChemicalObject dbo:ChemicalSubstance dbo:Drug owl:Thing wikidata:Q8386
rdfs:label
Полатузумаб ведотин ポラツズマブ ベドチン Polatuzumab vedotin Polatuzumab vedotine
rdfs:comment
Polatuzumab vedotine (merknaam Polivy) is een cytostaticum gekoppeld aan een monoklonaal antilichaam gericht tegen . Het middel is ontwikkeld door Genentech en Roche. Het middel wordt sinds 2020 ingezet tegen het diffuus grootcellig B-cellymfoom en folliculair lymfoom, en soms bij andere laaggradige lymfomen. Полатузумаб ведотин — конъюгат антитело-препарат для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2019). Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab after at least two prior therapies. The drug was developed by Genentech (subsidiary of Roche). ポラツズマブ ベドチン(Polatuzumab vedotin)は、がん治療用に設計された抗体薬物複合体(ADC)である。米国食品医薬品局は2019年6月、ベンダムスチンおよびリツキシマブとの併用によるびまん性大細胞型B細胞リンパ腫(DLBCL)の治療薬としてポラツズマブ ベドチンを承認した。日本では2021年3月に再発または難治性のDLBCLに対して承認され、同年12月には未治療のDLBCLに対する適応拡大が申請された。
foaf:homepage
n16:U.S.
dcterms:subject
dbc:Antibody-drug_conjugates dbc:Hoffmann-La_Roche_brands dbc:Genentech_brands dbc:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors dbc:Orphan_drugs
dbo:wikiPageID
46655721
dbo:wikiPageRevisionID
1124055378
dbo:wikiPageWikiLink
dbc:Hoffmann-La_Roche_brands dbr:Hoffmann-La_Roche dbc:Antibody-drug_conjugates dbc:Genentech_brands dbr:R-CHOP dbr:Food_and_Drug_Administration dbc:Breakthrough_therapy dbr:European_Medicines_Agency dbr:Genentech dbr:Bendamustine dbr:Large_B-cell_lymphoma dbr:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Antibody-drug_conjugate dbr:International_Nonproprietary_Name dbr:Orphan_drug dbr:Rituximab dbr:Priority_review dbc:Orphan_drugs dbr:CD79B
dbo:wikiPageExternalLink
n18:761121Orig1s000TOC.cfm n21:polatuzumab%20vedotin
owl:sameAs
freebase:m.0136_xpc dbpedia-ru:Полатузумаб_ведотин wikidata:Q19946115 dbpedia-nl:Polatuzumab_vedotine dbpedia-ja:ポラツズマブ_ベドチン yago-res:Polatuzumab_vedotin n24:uWnt
dbp:wikiPageUsesTemplate
dbt:Monoclonals_for_tumors dbt:Antineoplastic-drug-stub dbt:Drugs.com dbt:Keggcite dbt:Drugbox dbt:Reflist dbt:Use_dmy_dates dbt:Cite_web dbt:Portal_bar
dbp:atcSuffix
FX14
dbp:atcPrefix
L01
dbp:c
6670
dbp:casNumber
1313206
dbp:chemspiderid
none
dbp:drugbank
DB12240
dbp:h
10317
dbp:kegg
D10761
dbp:legalStatus
Rx-only
dbp:legalUs
Rx-only
dbp:medlineplus
a619039
dbp:n
1745
dbp:o
2087
dbp:s
40
dbp:source
zu/o
dbp:synonyms
DCDS4501A, RG7596, polatuzumab vedotin-piiq
dbp:target
dbr:CD79B
dbp:tradename
Polivy
dbp:type
mab
dbp:unii
KG6VO684Z6
dbo:abstract
Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab after at least two prior therapies. The drug was developed by Genentech (subsidiary of Roche). Polatuzumab vedotine (merknaam Polivy) is een cytostaticum gekoppeld aan een monoklonaal antilichaam gericht tegen . Het middel is ontwikkeld door Genentech en Roche. Het middel wordt sinds 2020 ingezet tegen het diffuus grootcellig B-cellymfoom en folliculair lymfoom, en soms bij andere laaggradige lymfomen. Полатузумаб ведотин — конъюгат антитело-препарат для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2019). ポラツズマブ ベドチン(Polatuzumab vedotin)は、がん治療用に設計された抗体薬物複合体(ADC)である。米国食品医薬品局は2019年6月、ベンダムスチンおよびリツキシマブとの併用によるびまん性大細胞型B細胞リンパ腫(DLBCL)の治療薬としてポラツズマブ ベドチンを承認した。日本では2021年3月に再発または難治性のDLBCLに対して承認され、同年12月には未治療のDLBCLに対する適応拡大が申請された。
dbp:dailymedid
Polatuzumab_vedotin
dbp:iupharLigand
8404
dbp:legalAu
S4
dbp:legalCa
Rx-only / Schedule D
dbp:legalEu
Rx-only
dbp:licenceEu
yes
dbp:licenceUs
Polivy
dbp:mabType
mab
dbp:pregnancyAu
D
dbp:pubchemsubstance
347911301
gold:hypernym
dbr:Antibody
prov:wasDerivedFrom
wikipedia-en:Polatuzumab_vedotin?oldid=1124055378&ns=0
dbo:wikiPageLength
9435
dbo:alternativeName
Polivy
dbo:casNumber
1313206-42-6
dbo:drugbank
DB12240
dbo:fdaUniiCode
KG6VO684Z6
dbo:kegg
D10761
dbo:medlinePlus
a619039
foaf:isPrimaryTopicOf
wikipedia-en:Polatuzumab_vedotin
Subject Item
dbr:List_of_therapeutic_monoclonal_antibodies
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
Subject Item
dbr:Polivy
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
dbo:wikiPageRedirects
dbr:Polatuzumab_vedotin
Subject Item
dbr:Polatuzumab_vedotin-piiq
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
dbo:wikiPageRedirects
dbr:Polatuzumab_vedotin
Subject Item
dbr:RG7596
dbo:wikiPageWikiLink
dbr:Polatuzumab_vedotin
dbo:wikiPageRedirects
dbr:Polatuzumab_vedotin
Subject Item
wikipedia-en:Polatuzumab_vedotin
foaf:primaryTopic
dbr:Polatuzumab_vedotin